Related Experiment Video
Updated: Aug 14, 2026
07:21
Subcutaneous Angiotensin II Infusion using Osmotic Pumps Induces Aortic Aneurysms in Mice
Published on: September 28, 2015
[Angioedema caused by angiotensin-converting enzyme inhibitors]
J Sojić-Rajcić1, M Bogić, V Tomić-Spirić
1Institute of Allergology and Immunology, Clinical Centre of Serbia, Belgrade.
Srpski Arhiv Za Celokupno Lekarstvo
|March 21, 2001
Summary
Angiotensin-converting enzyme inhibitors can cause angioedema, a rare side effect of hypertension treatment. This swelling, often appearing early, can also occur years into therapy due to the drug
Area of Science:
- Cardiology and Pharmacology
Background:
- Arterial hypertension is a common condition requiring pharmacologic management.
- Angiotensin-converting enzyme (ACE) inhibitors are frequently prescribed for hypertension.
- ACE inhibitors carry a risk of angioedema, a potentially serious adverse effect.
Observation:
- Angioedema typically manifests within the first week of ACE inhibitor therapy.
- Atypical presentations of angioedema can occur months to years after initiating ACE inhibitor treatment.
- The mechanism is likely a pharmacological effect rather than a true allergic reaction, particularly in susceptible individuals.
Findings:
- This paper details cases of angioedema associated with ACE inhibitor use.
- The study highlights the varied timing of angioedema onset.
- It suggests a non-allergic, pharmacologically mediated pathway for this adverse reaction.
Implications:
- Clinicians should maintain awareness of angioedema as a potential side effect of ACE inhibitors, even with long-term use.
- Understanding the pharmacological basis may guide risk assessment and management strategies.
- Further research into the specific risk factors and mechanisms is warranted to improve patient safety.
Related Concept Videos
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
01:25Antihypertensive Drugs: Direct Renin Inhibitors
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
01:30Angina I: Introduction
Definition and Symptoms: Angina (angina pectoris) is chest pain or discomfort caused by myocardial ischemia, which occurs when the heart muscle receives insufficient oxygen-rich blood. It typically manifests as pressing, squeezing, or crushing sensations in the chest and may radiate to the shoulders, arms, neck, jaw, or back.Primary Cause: In a healthy state, the coronary arteries can dilate (widen) to increase blood flow and meet the increased oxygen demand during physical activity or...